Subjects 18 to 55 years of age will be randomly assigned to take ponesimod or teriflunomide (Aubagio) pills daily; they have an equal chance of getting either treatment. The treatment will last for 108 weeks. An end-of-treatment visit will take place at Week 108. All subjects will enter the safety follow-up period (2 to 4 weeks). For an individual subject, the maximum duration of the study will be approximately 118 weeks (2.2 years).
Who may be Eligible
People 18-55 years of age with relapsing forms of multiple sclerosis